Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia
Masahiro Ogasawara1,2, Mamiko Miyashita2, Yuka Yamagishi3
1Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Introduction:
The prognosis of patients with relapsed or refractory acute leukemia is poor. In the present pilot study, we treated relapsed or refractory acute leukemia patients with Wilms' tumor 1 (WT1) peptide-loaded dendritic cells (DCs) and examined safety, clinical and immunological responses.
Methods:
Eleven eligible patients were enrolled. DCs were administered every 2-3 weeks with OK-432 adjuvant.
Results:
The treatment was well tolerated. The reduction of leukemia cells or the expression of WT1 mRNA was observed in four patients which was maintained for a significant period of time. All the responding patients manifested immune responses against WT1 which might be related to clinical outcome. Decreases in the absolute number of regulatory T cells were observed following vaccination, indicating that DC vaccinations may contribute to the reversal of immunosuppression.
Conclusion:
These results indicate that DC-based immunotherapy is safe and feasible for patients with acute leukemia.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...